BeiGene FY2025 EPS Forecast Reduced by Leerink Partnrs

BeiGene, Ltd. (NASDAQ:BGNE - Free Report) - Analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for BeiGene in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of $0.73 for the year, down from their prior estimate of $0.79. The consensus estimate for BeiGene's current full-year earnings is ($5.00) per share. Leerink Partnrs also issued estimates for BeiGene's FY2026 earnings at $8.11 EPS and FY2027 earnings at $13.54 EPS.

BeiGene (NASDAQ:BGNE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.15%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. During the same quarter in the prior year, the firm earned $2.01 earnings per share. The firm's quarterly revenue was up 28.2% compared to the same quarter last year.

Other equities research analysts have also issued research reports about the stock. TD Cowen lifted their price objective on shares of BeiGene from $254.00 to $260.00 and gave the company a "buy" rating in a research note on Wednesday. StockNews.com upgraded BeiGene from a "hold" rating to a "buy" rating in a research note on Wednesday. Citigroup increased their price objective on BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a report on Thursday, August 8th. JPMorgan Chase & Co. boosted their target price on BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a report on Tuesday, October 22nd. Finally, JMP Securities initiated coverage on BeiGene in a report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, BeiGene currently has an average rating of "Moderate Buy" and an average price target of $247.07.

BeiGene Stock Down 1.1 %

NASDAQ BGNE traded down $2.16 during trading on Thursday, reaching $193.29. The company's stock had a trading volume of 213,475 shares, compared to its average volume of 264,875. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $18.83 billion, a PE ratio of -23.68 and a beta of 0.63. BeiGene has a 1-year low of $126.97 and a 1-year high of $248.16. The business has a 50-day moving average price of $212.91 and a 200-day moving average price of $181.72.

Institutional Trading of BeiGene

Several institutional investors have recently modified their holdings of BGNE. Portland Investment Counsel Inc. increased its stake in BeiGene by 50.0% in the third quarter. Portland Investment Counsel Inc. now owns 3,000 shares of the company's stock valued at $674,000 after acquiring an additional 1,000 shares during the period. Verition Fund Management LLC acquired a new position in shares of BeiGene in the 3rd quarter worth approximately $281,000. Capstone Investment Advisors LLC bought a new position in shares of BeiGene during the 3rd quarter worth approximately $1,192,000. Walleye Capital LLC boosted its stake in BeiGene by 50.1% in the 3rd quarter. Walleye Capital LLC now owns 26,721 shares of the company's stock valued at $5,999,000 after buying an additional 8,924 shares in the last quarter. Finally, FMR LLC grew its position in BeiGene by 0.8% in the third quarter. FMR LLC now owns 1,660,011 shares of the company's stock valued at $372,689,000 after acquiring an additional 12,855 shares during the period. Institutional investors and hedge funds own 48.55% of the company's stock.

Insiders Place Their Bets

In related news, insider Titus B. Ball sold 137 shares of the business's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Xiaobin Wu sold 5,556 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The disclosure for this sale can be found here. Insiders have sold a total of 23,070 shares of company stock valued at $4,901,050 in the last three months. Company insiders own 7.43% of the company's stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.